ATYR PHARMA INC (LIFE)

US0021202025 - Common Stock

1.91  +0.02 (+1.06%)

After market: 1.94 +0.03 (+1.57%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to LIFE. LIFE was compared to 599 industry peers in the Biotechnology industry. The financial health of LIFE is average, but there are quite some concerns on its profitability. LIFE is valied quite expensively at the moment, while it does show a decent growth rate.



1

1. Profitability

1.1 Basic Checks

In the past year LIFE has reported negative net income.
In the past year LIFE has reported a negative cash flow from operations.
In the past 5 years LIFE always reported negative net income.
LIFE had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -34.49%, LIFE is in the better half of the industry, outperforming 66.55% of the companies in the same industry.
LIFE has a Return On Equity of -43.85%. This is in the better half of the industry: LIFE outperforms 69.93% of its industry peers.
Industry RankSector Rank
ROA -34.49%
ROE -43.85%
ROIC N/A
ROA(3y)-39.49%
ROA(5y)-49.83%
ROE(3y)-48.49%
ROE(5y)-71.85%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

LIFE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

4

2. Health

2.1 Basic Checks

LIFE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LIFE has been increased compared to 1 year ago.
LIFE has more shares outstanding than it did 5 years ago.
LIFE has a worse debt/assets ratio than last year.

2.2 Solvency

LIFE has an Altman-Z score of -2.83. This is a bad value and indicates that LIFE is not financially healthy and even has some risk of bankruptcy.
LIFE's Altman-Z score of -2.83 is in line compared to the rest of the industry. LIFE outperforms 43.07% of its industry peers.
LIFE has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.01, LIFE is in line with its industry, outperforming 41.55% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -2.83
ROIC/WACCN/A
WACC10.99%

2.3 Liquidity

A Current Ratio of 8.32 indicates that LIFE has no problem at all paying its short term obligations.
LIFE's Current ratio of 8.32 is fine compared to the rest of the industry. LIFE outperforms 70.10% of its industry peers.
A Quick Ratio of 8.32 indicates that LIFE has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 8.32, LIFE is in the better half of the industry, outperforming 70.27% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.32
Quick Ratio 8.32

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 41.21% over the past year.
LIFE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 191.38% yearly.
EPS 1Y (TTM)41.21%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q56.52%
Revenue 1Y (TTM)N/A
Revenue growth 3Y191.38%
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

Based on estimates for the next years, LIFE will show a very strong growth in Earnings Per Share. The EPS will grow by 20.59% on average per year.
The Revenue is expected to grow by 291.17% on average over the next years. This is a very strong growth
EPS Next Y40.46%
EPS Next 2Y20.65%
EPS Next 3Y11.68%
EPS Next 5Y20.59%
Revenue Next Year92.17%
Revenue Next 2Y477.12%
Revenue Next 3Y252.22%
Revenue Next 5Y291.17%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LIFE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LIFE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.65%
EPS Next 3Y11.68%

0

5. Dividend

5.1 Amount

LIFE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ATYR PHARMA INC

NASDAQ:LIFE (2/23/2024, 7:00:02 PM)

After market: 1.94 +0.03 (+1.57%)

1.91

+0.02 (+1.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap111.85M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -34.49%
ROE -43.85%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 8.32
Quick Ratio 8.32
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)41.21%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y40.46%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3Y191.38%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y